Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT04285112
Active, not recruiting Observational

SPRINT: Signature for Pain Recovery IN Teens

NCT04285112 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2020-09-28
Last updated
2025-09-11

Condition(s) studied

Pain, ChronicPainJoint PainMusculoskeletal Pain

Study summary

To identify biological and phenotypic prognostic markers of recovery vs. persistence of pain and functional disability in adolescents with chronic musculoskeletal pain.

Eligibility

Sex
ALL
Min age
11 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. The child has a diagnosis of Chronic widespread pain or Chronic primary musculoskeletal pain (other than orofacial) derived from ICD-11 (MG30.0; chronic primary pain is pain in 1 or more anatomic regions that persists for \> 3 months, is associated with significant distress or functional disability and cannot be better explained by another chronic pain condition (e.g., arthritis, lupus) 2. Age between 11-18 years 3. Moderate to Severe Functional Disability (FDI ≥13) 4. English proficiency (reading, speaking) 5. Moderate to severe average pain (VAS ≥30/100) Exclusion Criteria: 1. Significant cognitive impairment (e.g., severe brain injury) 2. Claustrophobia 3. Significant medical disease (e.g., systemic or central nervous system) 4. Severe psychiatric or neurological conditions (e.g., eating disorder, psychosis) 5. Pregnancy 6. MRI incompatibility (braces, pacemaker) 7. Weight \> 285 lbs. 8. History of \> 1 month opioid treatment.

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Stanford University Palo Alto California
Cincinnati Children's Hospital Cincinnati Ohio
Hospital for Sick Children Toronto Ontario
University of Barcelona Barcelona Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04285112 on ClinicalTrials.gov ↗ ← All trials in Spain